Press Releases

Jul 28, 2026

Sofia Navarro

Press Releases

authID and MajorKey Technologies Expand Partnership Through OEM Agreement, Embedding Verified and PrivacyKey Across MajorKey's Identity Security Portfolio

authID announced an expanded OEM agreement with MajorKey Technologies to embed its Verified™, PrivacyKey™, and Proof™ biometric identity verification technologies directly into MajorKey’s identity security offerings. This allows MajorKey to deliver advanced privacy-preserving biometric verification across various high-risk identity workflows beyond…

AUID

Jul 28, 2026

Jordan Park

Press Releases

Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin

Nuwellis, Inc. announced the installation of its Aquadex SmartFlow systems at a leading pediatric hospital in Wisconsin, marking its entry into a new pediatric market and expanding its footprint in critical care. The company targets growth by developing clinical protocols for Aquadex therapy, which aids precise fluid removal in critically ill child…

NUWE

Jul 28, 2026

Ajmal Hussain

Press Releases

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic collaboration to develop a precision cognitive health platform combining Firefly's AI-powered FDA-cleared EEG/ERP brain biomarker system with personalized peptide protocols, such as Epitalon and Semax. This initiative aims to provide objective clinical measures to personalize…

AIFF

Jul 28, 2026

Priya Menon

Press Releases

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Clearmind Medicine Inc. announced the successful completion of treatment for all participants in Part A of its FDA-regulated Phase I/II trial evaluating CMND-100 for Alcohol Use Disorder (AUD). The company is currently analyzing the data and plans to proceed to the next trial phase, advancing its non-hallucinogenic neuroplastogen-based therapeutic …

CMND

Jul 28, 2026

Hana Yamamoto

Press Releases

Trevi Therapeutics to Participate in Upcoming August Conferences

Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough related to idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough, announced its management's participation in key August biotech conferences to discuss clinical progress and company strategy.

TRVI

Jul 28, 2026

Leila Farooq

Press Releases

Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET

Harvard Bioscience, Inc. has scheduled the announcement of its second quarter 2026 financial results for August 11, 2026, before market opening. The company will hold a conference call at 8:00 AM ET to discuss the results, providing analysts and investors with detailed insights into its performance.

HBIO

Jul 28, 2026

Maya Rios

Press Releases

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

Plus Therapeutics, a clinical-stage healthcare company focused on CNS cancers, announced upcoming presentations of its ReSPECT-LM clinical program and CNSide diagnostic platform at the 2026 SNO/ASCO CNS Metastases Conference. The company will also host a sponsored symposium on leptomeningeal metastases management. Additionally, Plus Therapeutics wi…

PSTV

Jul 28, 2026

Maya Rios

Press Releases

Hubbell Reports Second Quarter 2026 Results

Hubbell Incorporated (NYSE: HUBB) delivered solid Q2 2026 performance, reporting a 15% increase in net sales and a 12% rise in adjusted diluted EPS to $5.52. Organic sales growth was driven by strong demand in utility solutions and electrical solutions segments, fueled by megatrends like grid modernization and datacenter investments. Adjusted opera…

HUBB

Jul 28, 2026

Derek Hwang

Press Releases

Venus Concept Obtains Exclusive Distribution Rights for the HIRONIC Doublo 2.0 Device in US and Canada

Venus Concept Inc., a leader in medical aesthetic technology, has obtained exclusive rights to distribute HIRONIC's Doublo 2.0 device in the United States and Canada. The new device, which incorporates Cold Plasma and RF microneedling technologies, has received FDA 510(k) clearance and will be launched in the US in the second half of 2026. Venus Co…

VNU

Jul 28, 2026

Hana Yamamoto

Press Releases

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on novel therapies for rare skin diseases and vascular malformations, will announce its Q2 2026 financial results before market open on August 4, 2026, followed by a corporate update conference call. The company is developing therapies based on its QTORIN platform, with lead …

PVLA

Jul 28, 2026

Ajmal Hussain

Press Releases

3D Systems Enables First FDA Clearance for Implant from a Point-of-Care Institution

3D Systems played a pivotal role in enabling the Defense Health Agency and Walter Reed 3D Medical Applications Center to receive FDA premarket clearance for the Titanium Cranial Plate System, the first FDA-cleared implant granted to a point-of-care institution. This milestone exemplifies the advancement of additive manufacturing in clinical environ…

DDD

Jul 28, 2026

Marcus Reed

Press Releases

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Dyne Therapeutics announces FDA clearance of its Investigational New Drug application for DYNE-302, advancing its third clinical program leveraging the FORCE platform to treat facioscapulohumeral muscular dystrophy (FSHD), a rare progressive neuromuscular disorder with no approved therapies. The Phase 1 trial will assess safety, tolerability, pharm…

DYN

Jul 28, 2026

Priya Menon

Press Releases

ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform

ZenaTech has commenced flight testing of its Interceptor P-1, a low-cost, autonomous counter-UAS drone designed to physically intercept hostile drones. This marks a significant milestone in expanding its defense portfolio with affordable counter-drone solutions integrating AI and autonomous swarm operations. The company aims to address growing glob…

ZENA

Jul 28, 2026

Jordan Park

Press Releases

Riot Announces Second Quarter 2026 Earnings Conference Call

Riot Platforms, Inc., a leader in large-scale data centers and bitcoin mining, announced its Q2 2026 earnings call set for August 5, 2026. The company focuses on developing digital infrastructure and mining operations across Texas and Kentucky, with engineering facilities in Denver and Houston. The press release reiterates forward-looking statement…

RIOT

Jul 28, 2026

Caleb Monroe

Press Releases

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

Nasus Pharma, a clinical-stage biopharmaceutical company developing innovative intranasal therapies, announced the appointment of pharmaceutical industry veteran Brendan P. O'Grady as CEO. O'Grady will lead the next phase of growth with an emphasis on unlocking the commercial potential of NS002, an intranasal epinephrine treatment targeting a $2 bi…

NSRX

Jul 28, 2026

Priya Menon

Press Releases

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

PMGC Holdings Inc., through its subsidiary A&B Aerospace, has entered a long-term manufacturing agreement with Precision Aerospace & Defense Group to supply precision-machined aerospace and defense components. Additionally, PMGC made a $500,000 strategic equity investment in PAD Group, further aligning their partnership. This collaboration position…

ELAB

Jul 28, 2026

Priya Menon

Press Releases

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals reported robust second quarter 2026 financial results highlighted by 55% year-over-year net product revenue growth for ARCALYST®, reaching $243.6 million in Q2. The company raised its full-year 2026 ARCALYST revenue guidance to $980-$995 million. Clinical progress continues with promising Phase 2 data for KPL-387 supporting …

KNSA

Jul 28, 2026

Leila Farooq

Press Releases

Traveling with a baby? French families are keeping summer flights short, says KAYAK

According to KAYAK, a travel search engine owned by Booking Holdings, French families traveling with children under two in summer 2026 prefer shorter flights mainly to Mediterranean destinations within about three hours of France. Popular locations include Spain, Portugal, Morocco, and Tunisia. The travel pattern reflects the need to minimize fligh…

BKNG

Jul 28, 2026

Hana Yamamoto

Press Releases

DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment

Digital Currency X Technology Inc. has announced comprehensive upgrades to its DexTrader on-chain data platform, enhancing data architecture, omnichain capabilities, and user services. The company aims to target the digital asset information niche for token-based derivatives, yield instruments, and collateralized assets, positioning DexTrader as a …

DCX

Jul 28, 2026

Sofia Navarro

Press Releases

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Biomedical announced three new customer agreements, including a late-stage regenerative medicine program and two early-stage projects supporting medical technology development. These agreements diversify Lifecore's pipeline and are expected to contribute to revenue starting in 2028, reinforcing its position as a key player in the CDMO mark…

LFCR

Jul 28, 2026

Sofia Navarro

Press Releases

Midera Food Processing Schedules Second Quarter 2026 Earnings Release and Conference Call

Midera Food Processing, a provider of food processing equipment and automation solutions, will release its fiscal Q2 2026 earnings after market close on August 13, 2026. Management will hold a conference call to discuss results the same day. The company happens to serve industrial protein, bakery, and snack producers worldwide.

MFP

Jul 28, 2026

Caleb Monroe

Press Releases

DoubleDown Interactive to Report 2026 Second Quarter Results on August 11 and Host Conference Call and Webcast

DoubleDown Interactive, a developer and publisher of digital games with a focus on social casino experiences, will release financial results for the second quarter of 2026 after market close on August 11. The company will host a conference call and webcast to discuss the results and provide a business update.

DDI

Jul 28, 2026

Nina Shah

Press Releases

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Arvinas, Inc., a biotechnology company focusing on targeted protein degradation therapies, announced that it will report its second quarter 2026 financial results and provide a corporate update during a live webcast on August 4, 2026. The company continues to advance multiple drug candidates in clinical development for neurodegenerative disorders, …

ARVN

Jul 28, 2026

Derek Hwang

Press Releases

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

Cullinan Therapeutics announced a positive End-of-Phase 1 meeting with the FDA regarding their novel T cell engager CLN-049 for acute myeloid leukemia (AML). The FDA's feedback supports initiating a potentially registrational Phase 2 study in relapsed/refractory AML patients in Q3 2026. CLN-049 targets FLT3-expressing leukemia cells and has receive…

CGEM

Jul 28, 2026

Hana Yamamoto

Press Releases

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Atea Pharmaceuticals announced that its oral antiviral combination Bemnifosbuvir/Ruzasvir (BEM/RZR) achieved statistical non-inferiority to the standard treatment Sofosbuvir/Velpatasvir (SOF/VEL) in the Phase 3 C-BEYOND trial for treating chronic Hepatitis C Virus (HCV) infection. The 8-week BEM/RZR regimen demonstrated high cure rates across patie…

AVIR